Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA reduced its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 11.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 354,455 shares of the biopharmaceutical company's stock after selling 46,394 shares during the period. Pictet Asset Management Holding SA owned 0.62% of Agios Pharmaceuticals worth $11,647,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in AGIO. Venturi Wealth Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. Wingate Wealth Advisors Inc. purchased a new position in Agios Pharmaceuticals in the fourth quarter worth approximately $53,000. KBC Group NV increased its stake in Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Agios Pharmaceuticals during the third quarter worth $146,000. Finally, AlphaQuest LLC lifted its stake in shares of Agios Pharmaceuticals by 106.2% in the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after purchasing an additional 2,338 shares during the last quarter.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO traded up $0.14 during mid-day trading on Monday, hitting $25.90. The company had a trading volume of 1,136,441 shares, compared to its average volume of 710,787. The company has a market capitalization of $1.48 billion, a PE ratio of 2.28 and a beta of 0.83. The business's 50-day simple moving average is $32.40 and its 200 day simple moving average is $40.04. Agios Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $62.58.

Remove Ads

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AGIO. Scotiabank raised their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price target on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Royal Bank of Canada lifted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a report on Tuesday, December 10th. Finally, StockNews.com lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $56.57.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.